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ABSTRACT
Objective: The main objective present research work an attempt has been made to prepare fast dissolving tablets of Valsartan by using vacuum 
drying technique. Camphor, Urea and Menthol are used as a sublimating agent. Valsartan is an oral antihypertensive agent, with problems of variable 
bioavailability and bioequivalence related to its poor water solubility. Valsartan is an angiotensin II type 1 receptor antagonist indicated in the 
treatment of hypertension. 
Methods: The prepared tablets Valsartan  fast dissolving tablets were   evaluated  for  various  parameters  like  weight  variation,  hardness, friability, 
disintegration time, drug content, water absorption ratio, wetting time, in- vitro drug release, FTIR, DSC  studies and short term stability studies. The 
blend was examined for the pre-compressional and post-compressional parameter. 
Results and Discussions: The values of pre-compression parameters evaluated were within prescribed limits and indicated good free flowing 
property. All the post-compressional parameter are evaluated were prescribed limits and results were within IP acceptable limits. Based on the in-
vitro disintegration time and dissolution studies formulations SC2 and SC3 were found to be promising and showed a disintegration time of 24 sec 
and 16 sec respectively. Formulation SC3 containing camphor showed highest drug release 99.4% within 10 min. IR spectral analysis and DSC study 
showed that there was no drug interaction with formulation additives of the tablet as there is no variation and shift in the position of characteristic 
absorption bands it can be justified there is no interaction between drug and polymer. Short term stability studies on the formulations indicated that 
there are no significant change in hardness, friability, drug content and in-vitro drug release (p<0.05). 
Conclusion: The  results  concluded  that  fast  dissolving  tablets  of  Valsartan  showing enhanced dissolution may lead to improved bioavailability 
and effective therapy by using sublimation method.
Keywords: Fast dissolving tablet, Valsartan, Crospovidone, Camphor, Urea, Disintegration time.
INTRODUCTION
Valsartan is an angiotensin II receptor antagonist and is widely used 
in the management of hypertension to reduce cardiovascular mortality 
in patients with left ventricular dysfunction following myocardial 
infarction and in the management of heart failure. Valsartan is rapidly 
absorbed after oral dose with a bioavailability of about 23%. Peak 
plasma concentrations occur 2-4 hrs, and its plasma half-life is about 
7.5 hrs after an oral dose. In the management of hypertension, Valsartan 
is given in a dose of 80 mg once daily [1-3].
Most pharmaceutical forms for oral administration are formulated for 
direct ingestion, for chewing, for prior dispersion and/or dissolution 
in water; some of them are absorbed in the mouth. Elderly individuals 
have difficulty in swallowing when prescribed in conventional tablet 
and capsule form [4-6]. The problem of swallowing is also evident in 
pediatrics, psychiatric as well as traveling patients who may not have 
ready access to water [7]. The rapidly disintegrating tablet in the mouth 
or orodispersible tablets overcome all the above problems and thus 
offer an alternate form of oral medication, which provide patients with 
a more convenient means of taking their medication [8]. Addition of 
super disintegrating agent in the formulation is one of the approaches 
to formulate orodispersible tablets [9-15]. Orally disintegrating 
tablets (ODTs) rapidly disintegrate in the mouth without chewing 
on oral administration and without the need for water, unlike other 
drug delivery systems, and conventional oral solid immediate-release 
dosage form. ODT dosage forms, also commonly known as fast melt, 
quick melts, fast disintegrating and orodispersible systems have the 
unique property of disintegrating the tablet in the mouth in seconds. 
The desired criteria for the FDT they should have a pleasing mouth 
feel, leave minimal or no residue in the mouth after oral administration 
and not require water to swallow, but it should dissolve or disintegrate 
in the mouth in a matter of seconds [16,17]. Most commonly used 
methods to prepare these tablets are; freeze-drying/Lyophilization [18] 
tablet molding [19] and direct compression methods [20]. Lyophilized 
tablets show a very porous structure, which causes quick penetration 
of saliva into the pores when placed in the oral cavity [18,21]. Molded 
tablets dissolve completely and rapidly. However, lack of strength and 
taste masking are of great concern [22]. Main advantages of direct 
compression are low manufacturing cost and high mechanical integrity 
of the tablets [23]. Therefore, direct compression appears to be a better 
option for manufacturing of tablets. The key to the rapid disintegration 
of fast dissolving tablets (FDT) is the preparation of a porous structure in 
the tablet matrix. To generate such a porous matrix, volatile ingredients 
are incorporated in the formulation that is later subjected to a process 
of sublimation [24-26]. Highly volatile ingredients such as camphor, 
menthol, and urea may be compressed along with other excipients into 
a tablet. This volatile material is then removed by sublimation leaving 
behind a highly porous matrix. In present research work, an attempt 




Valsartan was procured from Gift sample from Dr. Reddy’s Lab, 
Hyderabad. Mannitol, MCC, aspartame, talc, and magnesium stearate 
purchased from S.D. Fine chem., Mumbai. All other materials were of 
analytical reagent grade.
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Preparation of FDT by direct compression technique [27]
The basic principle involved in preparing FDT by sublimation technique 
shown in Fig. 1 using inert solid ingredients (urea, camphor, and 
menthol) and crospovidone were added to other tablet excipient and 
the blend was compressed into a tablet. Removal of volatile material 
by sublimation generated a porous structure. Accurately weighed 
ingredients were sifted through sieve no. 44 and thoroughly mixed 
for 10 minutes and magnesium stearate and other ingredients were 
added to the blend and thoroughly mixed. The tablets were compressed 
using Rimek tablet punching machine. The composition of the tablets 
was given in Table 1. The compressed tablets were than subjected to 
sublimation at 50°C for 60 minutes.
Evaluation of Valsartan tablets
Micromeritic properties of powder blend of tablets before 
compression
The prepared tablet blends are evaluated for different tests such as 
the angle of repose, apparent bulk density, tapped density, percent 
compressibility, and Hausner ratio.
Evaluation of Valsartan FDT [28-31]
Weight variation
The average weight of 20 tablets is calculated using an electronic 
balance. Individual weight of each tablet is calculated and compared 
with the average weight. The mean±standard deviation (SD) and 
relative SD were noted. The tablets meet USP specifications if no more 
than 2 tablets outside the percentage limit and if no tablet differs by 
more than 2 times the percentage limit.
Tablet thickness
Randomly 10 tablets should be taken, and thickness was measured for 
each tablet by placing it between two anvils and rotating the sliding 
knob until the tablet was tightly fitted and the reading was noted.
Hardness and friability
Tablet hardness has been defined as “the force required to break a tablet 
in a diametric compression test.” Hardness of tablet was determined 
using a Pfizer tablet hardness tester. Friability of 10 tablets from each 
formulation was determined using the Roche friabilator (Campbell 
Electronics, Mumbai, India). This device subjects a no of tablets to the 
combined effect of abrasions and shock by utilizing a plastic chamber 
that revolves at 25 rpm dropping the tablets at a distance of 6 inches 
with each revolution. A pre-weighed sample of tablets was placed in 
the friabilator, which was then operated for 100 revolutions. Tablets 
were dusted and re-weighed. Percentage friability of tablets <1% was 
considered acceptable.








Initial wt  of tablets.
100
Content uniformity
6 tablets from each formulation were taken randomly and powdered. 
A quantity of powder equivalent to the weight of one tablet was transferred 
into a 100 mL volumetric flask, containing phosphate buffer pH 5.8, and 
mixed thoroughly for few minutes, and the volume was made up to 
100 ml with phosphate buffer pH 5.8. The solution was filtered through 
Whatman filter paper and suitably diluted with the same medium, and 
the drug content was estimated from the standard plot by measuring the 
absorbance at 250 nm using a UV-Visible spectrophotometer.
In-vitro disintegration time
The process of breakdown of a tablet into smaller particles is called as 
disintegration. The in-vitro disintegration time of a tablet was determined 
using disintegration test apparatus as per I.P. specifications. Place one 
tablet in each of the 6 tubes of the basket. Add a disc to each tube and run 
the apparatus using pH 5.8 (simulated saliva fluid) maintained at 37±2°C 
as the immersion liquid. The assembly should be raised and lowered 
between 30 cycles per minute in the pH 5.8 maintained at 37± 2°C. The 
time in seconds taken for complete disintegration of the tablet with no 
palpable mass remaining in the apparatus was measured and recorded.
Wetting time and water absorption ratio
The wetting time of the tablets was measured using a simple procedure. 
Five circular tissue papers of 10 cm diameter were placed in a petri 
dish with a 10 cm diameter. About 10 mm of water containing a water-
Fig. 1: Schematic diagram of vacuum drying technique for design 
of fast dissolving tablets




SU1 SU2 SU3 SC1 SC2 SC3 SMI SM2 SM3
Valsartan 80 80 80 80 80 80 80 80 80
Crospovidone 16 16 16 16 16 16 16 16 16
Urea 10 20 30 - - - - - -
Camphor - - - 10 20 30 - - -
Menthol - - - - - - 10 20 30
Aspartame 2 2 2 2 2 2 2 2 2
D-Mannitol 54 44 34 54 44 34 54 44 34
MCC 20 20 20 20 20 20 20 20 20
PVP 15 15 15 15 15 15 15 15 15
Talc 1 1 1 1 1 1 1 1 1
Mg stearate 2 2 2 2 2 2 2 2 2
Total 200 200 200 200 200 200 200 200 200
Note: MCC: Microcrystalline cellulose (Avicel PH-102), PVP: Poly vinyl pyrrolidone, MgSt: Magnesium stearate
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soluble dye was added to the petri dish. A tablet was carefully placed 
on the surface of tissue paper in the petri dish at room temperature. 
The time required for water to reach the upper surface of the tablets 
and completely wet them was noted as the wetting time. To check for 
reproducibility, the measurements were carried out (n = 6), and the 
mean value was calculated.
The weight of the tablet before keeping in the petri dish was noted (Wb). 
The wetted tablet from the petri dish was taken and reweighed (Wa). 
The water absorption ratio, R, was determined according to the 
following equation:
R = 100 (Wa - Wb)/Wb
Where, Wb and Wa are the weight before and after water absorption, 
respectively. Measurement of wetting time of a tablet was shown in Fig. 2.
In-vitro dissolution studies [32]
Dissolution rate was studied using USP Type-II apparatus (USP XXIII 
Dissolution Test Apparatus at 50 rpm) using 900 ml of buffer pH (5.8) 
(simulated saliva fluid) as dissolution medium. Temperature of 
the dissolution medium was maintained at 37±2°C, an aliquot of 
dissolution medium was withdrawn at every 2 minutes interval and 
filtered. The absorbance of filtered solution was measured by UV 
spectrophotometric method at 250 nm, and concentration of the drug 
was determined from the standard calibration curve.
In-vitro drug release studies details
Apparatus used: USP XXIII dissolution test apparatus
Dissolution medium: 5.8 pH phosphate buffer solution
Dissolution medium volume: 900 ml
Temperature: 37±0.5°C
Speed of basket paddle: 35 rpm
Sampling intervals: 2 minutes
Sample withdrawn: 5 ml
Absorbance measured: 250 nm
Compatibility studies
Infrared (IR) studies
IR spectra for pure drug Valsartan and SC2 and SC3 powdered tablets 
were recorded in Infrared spectrophotometer with KBr pellets.
Differential scanning calorimetry (DSC) studies
DSC studies were carried out pure drug Valsartan and best formulations 
such as SC2 and SC3. DSC scan of about 5 m accurately weighed 
Valsartan and optimized formulations were performed by an automatic 
thermal analyzer system (DSC60 Shimadzu Corporation, Japan). Sealed 
and perforated aluminum pans were used in the experiments for all the 
samples. Temperature calibrations were performed using indium as 
standard. An empty pan sealed in the same way as for the sample was 
used as a reference. The entire samples were run at a scanning rate of 
10°C/minutes from 50°C to 300°C.
Stability studies [33-34]
•	 Stability	of	a	drug	has	been	defined	as	 the	ability	of	a	particular	
formulation,	 in	a	specific	container,	 to	remain	within	 its	physical,	
chemical,	therapeutic,	and	toxicological	specifications
•	 The	purpose	of	 stability	 testing	 is	 to	provide	 evidence	on	how	
the quality of a drug substance or drug product varies with time 
under	 the	 influence	of	a	variety	of	environmental	 factors	such	as	
temperature, humidity an light and enables recommended storage 
conditions, re-test periods, and shelf lives to be established
	 ICH	specifies	the	length	of	study	and	storage	conditions:
•	 Short-term	testing	25±2°C/60% RH±5% for 12 months
•	 Accelerated	testing	40±2°C/75% RH±5% for 6 months
The present study, stability studies were carried out at 25°C/60% and 
40°C/75% RH for a specific time period up to 3-month for the selected 
formulations.
RESULT AND DISCUSSION
Valsartan is an oral antihypertensive agent, with problems of variable 
bioavailability and bioequivalence related to its poor water solubility. 
In the present research work, an attempt has been made to prepare 
FDT of valsartan using vacuum drying technique. The values of 
pre-compressional parameters were within prescribed limit as per 
USP XXVII and indicate good flow properties. The results were shown 
in Table 2.
All the post-compressional parameter are evaluated were prescribed 
limits and results were within IP acceptable limits. Results were 
shown in Table 3. In all the formulations, hardness test indicated 
good mechanical strength ranges from 2.6 to 3.3 kg/cm². The 
friability range is 0.63-0.74% to be well within the approved range 
(<1%) indicated that tablet had good mechanical resistance. The 
weight variation was found in all designed formulations in the 
range 195-200 mg. All the tablets passed weight variation test as 
the average percentage weight variation was within 7.5%, i.e., in 
the pharmacopeia limits. The thickness was almost uniform in all 
the formulations and values ranged from 3.48 mm to 3.74 mm. The 
standard deviation values indicated that all the formulations were 
within the range.
The in-vitro disintegration time is measured by the time taken to 
undergo complete disintegration. Rapid disintegration within 2 m 
was observed in all the formulations. The in-vitro disintegration 
data is tabulated in Table 4. The in-vitro disintegration time of FDT 
was found to be 16-55 seconds which is in the range of fulfilling the 
official requirements. By the addition of super disintegrants, the 
disintegration time increased significantly (p<0.05) tablets prepared. 
The disintegration time decreased significantly regardless of the 
diluents used. It is because tablets prepared by sublimation method 
rapidly exhibits high pores and disintegrate the tablet rapidly. Above 
results shows that tablets prepared with crospovidone and camphor 
(sublimation method) showed least disintegration time in comparison 
with the all other formulations because of their lowest hardness and 
the porous structure.
Wetting time is closely related to the inner structure of the tablet. 
The results of wetting time are shown in Table 4. The wetting time 
of valsartan tablets prepared by sublimation method were found to 
be in the range of 17.18-53.37 seconds. Promising formulation SC3 
(camphor) showed a wetting time of 17.18 seconds, which facilitate 
the faster dispersion in the mouth. The water absorption ratio in the 
range 46.45-71.48%. The percentage drugs content of the tablets were 
found to be between 97.46 and 99.66% of Valsartan. The results were 
within the range, and that indicated uniformity of mixing. The wetting 
Fig. 2: Simple method for the measurement of wetting time of a 
tablet
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time, water absorption ratios, and drug content results were tabulated 
in Table 4.
The dissolution rate was studied by USP Type-II apparatus (USP XXIII 
Dissolution Test Apparatus at 35 rpm) using 900 ml of phosphate buffer 
pH (5.8) as dissolution medium. The dissolution release profiles of 
valsartan from the tablets are shown in Figs. 3-5. The tablet prepared 
by sublimation technique and the dissolution rate of the tablet was 
increased with increase in the concentration of camphor. Formulation 
SC3 containing camphor showed the highest drug release 99.79% 
in 10 minutes. This may be due to their lowest hardness, and the 
Table 2: Pre-compression parameters of powder blend of vacuum drying technique
FC Bulk density (g/cm3)* Tapped density (g/cm3)* Angle of repose (θ)* Hausner’s ratio* Carr’s index (%)*
SC1 0.47±0.24 0.55±0.12 28.14±0.21 1.14±0.02 14.54±0.26
SC2 0.44±0.22 0.49±0.14 22.05±0.17 1.09±0.02 10.20±0.42
SC3 0.54±0.25 0.62±0.11 26.92±0.12 1.13±0.02 12.90±0.26
SU1 0.49±0.03 0.70±0.02 23.12±1.49 1.13±0.03 21.42±0.23
SU2 0.53±0.01 0.71±0.02 23.04±1.71 1.13±0.04 23.72±0.14
SU3 0.55±0.03 0.72±0.03 24.31±1.68 1.13±0.05 27.60±0.26
SM1 0.56±0.03 0.72±0.02 27.77±1.65 1.13±0.06 17.24±0.23
SM2 0.51±0.17 0.58±0.14 27.85±0.21 1.13±0.01 21.76±0.14
SM3 0.43±0.18 0.49±0.34 22.36±0.14 1.13±0.01 22.24±0.23
*Average of three determinations
Table 3: Post-compression parameters Valsartan fast dissolving tablets
FC Hardness* (kg/cm²)±SD Friability (%)±SD Thickness* (mm)±SD Weight variation* (mg)±SD
SC1 2.9±0.09 0.45±0.07 2.34±0.09 199.63±1.7
SC2 2.8±0.06 0.81±0.09 2.45±0.07 197.18±1.0
SC3 2.4±0.04 0.54±0.12 2.12±0.04 200.37±0.6
SU1 2.9±0.2 0.53±0.07 2.22±0.03 198.33±1.1
SU2 3.1±0.1 0.67±0.09 2.33±0.09 200.14±1.5
SU3 3.0±0.1 0.65±0.08 3.10±0.09 199.82±1.9
SM1 3.2±0.07 0.17±0.29 2.17±0.06 202.22±0.9
SM2 3.4±0.13 0.62±0.05 2.62±0.07 199.59±1.3
SM3 3.3±0.22 0.16±0.07 2.65±0.05 199.56±1.7
*Average of three determinations
Table 4: Post-compression parameters Valsartan fast dissolving tablets
FC Disintegration time* (seconds)±SD Wetting time* (seconds)±SD Water absorption ratio*±SD Drug content* (%)±SD
SC1 29.16±1.2 29.15±1.4 51.28±1.2 99.20±0.5
SC2 24.16±1.2 23.23±1.5 53.63±1.2 99.55±0.7
SC3 16.16±1.4 17.18±1.2 71.48±1.1 98.76±0.8
SU1 31.92±1.6 34.73±1.4 64.26±1.2 99.20±0.5
SU2 35.44±1.2 30.03±1.6 67.56±1.5 99.55±0.7
SU3 46.61±1.4 44.32±1.5 71.14±0.4 98.76±0.8
SM1 55.12±1.2 49.68±1.6 74.35±0.9 99.92±1.2
SM2 43.92±1.6 42.85±1.8 46.45±0.91 100.08±0.8
SM3 48.20±1.4 53.37±0.82 47.58±1.3 99.38±1.3
*Average of three determinations
Fig. 3: Release profile of formulation containing camphor (SC1-
SC3)
Fig. 4: Release profile of formulation containing urea (SU1-SU3)
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porous structure was responsible for faster water uptake. Hence, it 
facilitates the wicking action of crospovidone in bringing about faster 
disintegration.
Based on the in-vitro disintegration time and dissolution studies 
formulations SC2 and SC3 were found to be promising and showed 
a disintegration time of 24 seconds and 16 seconds, respectively. 
Formulation SC3 containing camphor showed the highest drug release 
99.4% within 10 minutes. This may be due to their lowest hardness, and 
the porous structure was responsible for faster water uptake. Hence, it 




IR spectra for pure drug Valsartan and SC2 and SC3 powdered tablets 
were recorded in an infrared spectrophotometer with KBr pellets 
(Fig. 6). During the present research, the pure drug Valsartan was taken 
for study. The IR of this drug is collected which exhibited presence of 
various functionalities by their presence indicating the characteristic 
absorption peaks. The drug Valsartan exhibited a broad peak around 
3400/cm indicating the probable presence of characteristic absorption 
peak due to carboxylic acid. In this molecule, there is also N-H 
absorption almost in the same region hence resulting in the presence 
of broadening of the peak. This molecule contains a number of aromatic 
C-H peak by exhibiting a number of peaks around 2962/cm. C=0 peaks 
due to the carboxylic acid group as well as amide are absorbed at 
1732/cm, and 1600/cm suggesting that the drug taken for the present 
study contains functionalities such as N-H, COOH, C-H, C=0. In the next 
experiment, the formulation SC2 was taken. The resulting formulation is 
subjected for IR measurements. The spectrum obtained as indicated the 
presence of all characteristic features of the drug as well as excipients. 
At 3397 cm-1 the broad peak due to the drug molecule was observed, 
and C-H absorption peak of the aromatic ring system of the drug is also 
noticed at 2950/cm C=0 peaks of the drug were found to be present at 
1729/cm and 1632 cm. These data established that during the process 
of formulation no chemical reactions have taken place between drug 
and excipients. All the characteristic absorption peaks of the drug 
and excipients have remained intact. In SC3 formulation as there is no 
variation and shift in the position of characteristic absorption bands it 
can be justified, there is no interaction between drug and polymer.
DSC studies
The DSC thermograms of pure drug Valsartan and formulations SC2 
and SC3 were shown in Fig. 7. The pure drug Valsartan is taken for 
DSC studies which started melting at 72°C has completed the melting 
process completely at 79°C the melted liquid disappeared at 88°C. 
The sharp melting peak at 78°C indicates that compound is pure, and 
there is no mixture in it. In our sec experiment, i.e., formulation SC2 
thus obtained was taken for DSC studies but in this case, it is found 
that the melting process of the formulated product was delayed, and 
Fig. 5: Release profile of formulation containing menthol (SM1-
SM3)
Fig. 6: Fourier transform infrared spectra of pure drug Valsartan 
and formulations SC2 and SC3
Fig. 7: Differential scanning calorimetry thermograms of pure 
drug Valsartan and formulations SC2 and SC3
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sharp melting peak could not be obtained. It started at 89°C continued 
at 102°C. This indicates the physical mixture has been obtained during 
the process of formulation but not any reaction takes place. Next 
formulation SC3 similar observation is observed wherein the melting 
process has started at 88°C continued up to 105°C. Another hump was 
obtained at 126-138°C. Such nature of peaks indicates that constituents 
of the formulation have remained un-reacted resulting in delayed 
melting process. All these data suggest that during the process of 
formulation no interaction between drug and excipients. Only physical 
mixture is produced.
Table 5 shows the parameters of the tablets after stability study. After 
stability study of promised formulations, their hardness, drug content, 
and disintegration time were performed to detect the shelf life of 
promised formulations. In the case of tablet prepared by sublimation 
was decreased in disintegration time and wetting time was noticed. 
This may be due to the removed trance amount of camphor during 
stability study. Drug content of all the promised formulations was not 
changed after stability study.
CONCLUSION
The above results concluded that the FDT of Valsartan showing 
enhanced dissolution may lead to improved bioavailability and effective 
therapy using sublimation method. Based on the in-vitro disintegration 
time and dissolution studies formulations SC2 and SC3 were found to 
be promising and showed a disintegration time of 24 sec and 16 sec, 
respectively. Formulation SC3 containing camphor showed the highest 
drug release 99.4% within 10 min. Overall results indicate that 
formulation SC3, which contain 15% crospovidone, and camphor was a 
better one and satisfies all the criteria as fast dissolving tablet.
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